Advertisement
Canada markets closed

  • S&P/TSX

    21,969.24
    +83.86 (+0.38%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CAD/USD

    0.7316
    -0.0007 (-0.09%)
     

  • CRUDE OIL

    83.69
    +0.12 (+0.14%)
     

  • Bitcoin CAD

    87,487.38
    -1,351.46 (-1.52%)
     

  • CMC Crypto 200

    1,331.08
    -65.46 (-4.69%)
     

  • GOLD FUTURES

    2,349.30
    +6.80 (+0.29%)
     

  • RUSSELL 2000

    2,002.00
    +20.88 (+1.05%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,927.90
    +316.14 (+2.03%)
     

  • VOLATILITY

    15.03
    -0.34 (-2.21%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT RESULTS

Chevron, Exxon under pressure as falling natural gas prices hit earnings

Today's Research Reports on Emblem, OrganiGram Holdings, Oncolytics Biotech and Aptose Biosciences

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / August 10, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI Initiates Coverage on:

Emblem Corp.
https://rdinvesting.com/news/?ticker=EMC.V

OrganiGram Holdings Inc.
https://rdinvesting.com/news/?ticker=OGI.V

Oncolytics Biotech Inc.
https://rdinvesting.com/news/?ticker=ONC.TO

Aptose Biosciences Inc.
https://rdinvesting.com/news/?ticker=APS.TO

ADVERTISEMENT

Emblem's stock edged 0.83% lower Thursday, to close the day at $1.20. The stock recorded a trading volume of 441,760 shares, which was above its three months average volume of 298,366 shares. In the last year, Emblem's shares have traded in a range of 1.09 - 2.76. The stock is currently trading 56.52% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $1.26 is below its 200-day moving average of $1.47.Shares of Emblem have fallen approximately 47.37 percent year-to-date.

Access RDI's Emblem Corp. Research Report at:
https://rdinvesting.com/news/?ticker=EMC.V

On Thursday, shares of OrganiGram Holdings recorded a trading volume of 176,251 shares, which was below the three months average volume of 754,957 shares. The stock ended the day 0.77% lower at 5.18. The share price has gained 145.50% from its 52 week low with a 52 week trading range of 2.11 - 5.93. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $5.02 is greater than its 200-day moving average of $4.59. Shares of OrganiGram Holdings have gained approximately 26.34 percent year-to-date.

Access RDI's OrganiGram Holdings Inc. Research Report at:
https://rdinvesting.com/news/?ticker=OGI.V

Oncolytics Biotech's stock moved 2.73% higher Thursday, to close the day at $5.64. The stock recorded a trading volume of 13,521 shares, which was below its three months average volume of 32,395 shares. In the last year, Oncolytics Biotech's shares have traded in a range of 4.57 - 10.67. The share price has gained 23.41% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $6.90 is below its 200-day moving average of $7.19. Shares of Oncolytics Biotech have fallen approximately 16.59 percent year-to-date.

Access RDI's Oncolytics Biotech Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ONC.TO

On Thursday, shares of Aptose Biosciences recorded a trading volume of 57,635 shares, which was above the three months average volume of 40,714 shares. The stock ended the day 10.56% higher at 3.98. The share price has gained 142.68% from its 52 week low with a 52 week trading range of 1.64 - 5.97. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $4.42 is greater than its 200-day moving average of $4.28. Shares of Aptose Biosciences have gained approximately 43.17 percent year-to-date.

Access RDI's Aptose Biosciences Inc. Research Report at:
https://rdinvesting.com/news/?ticker=APS.TO

Our Actionable Research on Emblem Corp. (TSXV:EMC.V) and OrganiGram Holdings Inc. (TSXV:OGI.V) and Oncolytics Biotech Inc. (TSX:ONC.TO) and Aptose Biosciences Inc. (TSX:APS.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com